Patent: RE46856
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: RE46856
| Title: | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| Abstract: | This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. |
| Inventor(s): | Hentemann; Martin (Carlisle, MA), Wood; Jill (Fort Collins, CO), Scott; William (Guilford, CT), Michels; Martin (Koln, DE), Campbell; Ann-Marie (Monroe, CT), Bullion; Ann-Marie (Milford, CT), Rowley; Bruce R. (New Hope, PA), Redman; Aniko (Durham, NC) |
| Assignee: | Bayer Intellectual Property GMBH (Monheim, DE) |
| Application Number: | 15/398,916 |
| Patent Claims: | see list of patent claims |
Details for Patent RE46856
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2026-12-05 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2026-12-05 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2026-12-05 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2026-12-05 | |
| Baxalta Us Inc. | GAMMAGARD, GAMMAGARD S/D, IVEEGAM | immune globulin intravenous (human) | For Injection | 103133 | 02/18/1986 | ⤷ Try a Trial | 2026-12-05 |
| Baxalta Us Inc. | GAMMAGARD, GAMMAGARD S/D, IVEEGAM | immune globulin intravenous (human) | For Injection | 103133 | 07/27/2000 | ⤷ Try a Trial | 2026-12-05 |
| Hoffmann-la Roche Inc. | ROFERON-A | interferon alfa-2a | For Injection | 103145 | 06/04/1986 | ⤷ Try a Trial | 2026-12-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
